The future of pharmaceutical manufacturing could be orbiting Earth, according to Varda Space Industries CEO Will Bruey. His company recently demonstrated the capability to produce and return drug crystals from space, and he predicts that within a decade, routine space-based manufacturing could dramatically alter the industry. This, in turn, could significantly lower the cost of space access, impacting everything from scientific research to potential space-based employment within the next twenty years.
Varda isn’t aiming to simply exist in space, but rather to operate as an in-space industry, leveraging the unique environment of microgravity for practical applications. The company’s success hinges on proving a scalable and cost-effective method of creating pharmaceutical ingredients with enhanced properties that are difficult or impossible to produce on Earth.
The Promise of Space-Based Pharmaceutical Manufacturing
The core benefit of manufacturing in microgravity lies in the controlled environment it provides for crystal formation. On Earth, gravity and sedimentation interfere with the process, leading to inconsistencies in crystal size and purity. Varda claims that eliminating these forces allows for the creation of crystals with superior qualities, including increased stability, greater purity, and extended shelf life for medications.
In February 2024, Varda successfully completed a mission that brought crystals of ritonavir, an HIV medication, back to Earth. This achievement marked only the third time a private company has retrieved something from orbit, joining SpaceX and Boeing in this feat. The company utilizes a small, conical W-1 capsule, roughly the size of a kitchen trash can, for these returns.
The process involves lengthy manufacturing times in orbit – weeks or months for a single run – followed by a high-speed reentry into Earth’s atmosphere at over 30,000 kilometers per hour, exceeding Mach 25. A heat shield, developed by NASA, protects the cargo during this extreme phase, and a parachute ensures a safe landing.
Beyond Crystal Formation: A New Business Model
Varda’s long-term strategy differs drastically from traditional space companies focused on building out constellations like satellite internet providers. Instead, the company envisions a model driven by continuous demand. Each drug formulation requires repeated manufacturing runs and therefore, repeated launches.
This constant need translates into a predictable revenue stream for launch providers, incentivizing infrastructure investment and driving down costs. Bruey posits this could create a virtuous cycle, making increasingly complex and valuable products viable for space manufacturing. This scalability is a key component attracting investors, with the company raising $329 million as of July 2024.
While currently focused on pharmaceuticals, potentially expanding into biologics like monoclonal antibodies (a $210 billion market), Varda anticipates its model benefiting other industries requiring microgravity as well, such as semiconductor and fiber optic production. The creation of novel materials also stands to benefit.
Regulatory Hurdles and Hypersonic Testing
Varda’s initial success wasn’t without significant challenges. The company encountered a six-month delay in retrieving its W-1 capsule due to complex regulatory approvals. The primary issue stemmed from the lack of established protocols for commercial reentry landings, particularly at military test ranges like the Utah Test and Training Range.
This range is primarily used for weapons testing and military training, and Varda’s mission didn’t directly fit within that scope. Consequently, the company faced repeated postponements as priority was given to military operations, each delay requiring a new FAA reentry license. The situation highlighted the need for clear regulatory frameworks to support the growing commercial space sector.
However, Varda persevered, ultimately securing an FAA Part 450 operator license, granting it the ability to reenter the U.S. without resubmitting full safety documentation for each flight. This represents a significant milestone for the company and the broader industry.
Interestingly, the delays led to an unexpected secondary business opportunity: hypersonic testing. The W-1 capsule’s reentry at Mach 25 provides a unique environment for testing materials and sensors exposed to extreme temperatures and pressures. Varda is now collaborating with the Air Force Research Laboratory, offering in-situ measurements during reentry, a capability difficult and expensive to replicate on Earth.
The company’s success with these initial missions and its innovative business model are generating considerable interest in the broader space manufacturing landscape. As launch costs continue to decrease, and regulatory hurdles are overcome, the potential for commercial activity in orbit will likely increase. The exploration of in-space resources will also become more feasible.
Looking ahead, Varda aims to scale its pharmaceutical production capabilities and initiate clinical trials with drugs manufactured in space. The company’s next major milestone will be demonstrating the commercial viability of its technology and proving that low Earth orbit manufacturing can compete with traditional methods. Progress on this front, coupled with continued regulatory clarity, will be crucial to watch in the coming years. While significant hurdles remain, Varda’s vision of a thriving in-space economy is steadily gaining traction.
